Year: 2022
Type: article
Abstract: Homologous Recombination Deficiency (HRD) was initially described in cancers with germline mutations of BRCA1 and BRCA2 and thereafter in both sporadic and hereditary cancers carrying mutations or epigenetic inactivation of other genes involved in HR. Since cancers harbouring HRD are particularly susceptible to PARP inhibitors (PARPi), identifying methods to detect HRD that can accurately … Continued
Source: Annals of Research in Oncology
DOI: 10.48286/aro.2022.48
Authors: C. Piombino, L. Cortesi
Institution: Azienda Ospedaliero-Universitaria di Modena
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4282015396
